Aptalis gains double win from US FDA for pancreatic enzymes
This article was originally published in Scrip
Executive Summary
Aptalis Pharma won the US FDA's blessing on 1 March to market Ultresa (pancrelipase) and Viokace (pancrelipase) to treat exocrine pancreatic insufficiency (EPI), a condition in which the body is unable to properly digest fat, protein and carbohydrates and absorb nutrients.